Actively Recruiting

Phase 2
Age: 12Months - 30Years
All Genders
NCT06701812

Digoxin Medulloblastoma Study

Led by H. Lee Moffitt Cancer Center and Research Institute · Updated on 2026-02-27

23

Participants Needed

15

Research Sites

54 weeks

Total Duration

On this page

Sponsors

H

H. Lee Moffitt Cancer Center and Research Institute

Lead Sponsor

N

National Pediatric Cancer Foundation

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.

CONDITIONS

Official Title

Digoxin Medulloblastoma Study

Who Can Participate

Age: 12Months - 30Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must be older than 12 months and younger than 30 years at enrollment.
  • Patients must have relapsed non-WNT, non-SHH medulloblastoma confirmed by a certified assay.
  • Patients must have had at least one prior chemotherapy course and irradiation for medulloblastoma.
  • At least 3 months must have passed since prior craniospinal or local radiotherapy; at least 2 weeks since focal radiotherapy to metastatic sites.
  • More than 3 weeks since prior myelosuppressive chemotherapy, immunotherapy, or biologics; 7 days since colony-stimulating factor therapy.
  • Patients must have recovered from surgery with neurological stability for over 7 days.
  • Patients must have measurable residual tumor on MRI.
  • Patients must have a Lansky or Karnofsky performance status score of 50% or higher.
  • Patients must have normal organ and marrow function.
  • No evidence of Wolff-Parkinson-White syndrome or high-grade AV block on ECG.
  • No evidence of hypertrophic obstructive cardiomyopathy on echocardiogram.
  • Any recent palpitations or concerning heart findings must be cleared by a cardiologist.
  • Patients on dexamethasone are eligible if dosage is stable or decreasing for at least 7 days.
  • Neurologic status must be stable for at least 7 days before enrollment.
  • Females of childbearing potential must have a negative pregnancy test and agree to stop breastfeeding.
  • Women and men must agree to use effective contraception during the study.
  • Patients and/or guardians must understand and agree to informed consent or assent.
Not Eligible

You will not qualify if you...

  • Patients receiving other anticancer or investigational agents concurrently.
  • Patients taking digoxin currently for medulloblastoma treatment.
  • History of allergic reactions to digoxin or similar compounds.
  • Serious or uncontrolled cardiac arrhythmias, frequent premature ventricular contractions, or symptomatic sinus bradycardia.
  • Use of medications interfering with digoxin metabolism.
  • Uncontrolled illness or significant organ dysfunction that would affect treatment tolerance or study participation.
  • Psychiatric or social issues limiting compliance with study requirements.
  • Pregnant women or women unwilling to stop breastfeeding.
  • Patients unable to comply with safety monitoring requirements as judged by the investigator.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 15 locations

1

University of Alabama at Birmingham Children's of Alabama

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

Arkansas Childrens Hospital

Little Rock, Arkansas, United States, 72202

Actively Recruiting

3

Connecticut Children's Medical Center

Hartford, Connecticut, United States, 06106

Not Yet Recruiting

4

Children's National Medical Center

Washington D.C., District of Columbia, United States, 20010

Not Yet Recruiting

5

Nemours Jacksonville

Jacksonville, Florida, United States, 32207

Not Yet Recruiting

6

University of Miami

Miami, Florida, United States, 33136

Not Yet Recruiting

7

Johns Hopkins All Children's

St. Petersburg, Florida, United States, 33701

Not Yet Recruiting

8

St. Joseph's Children's Hospital

Tampa, Florida, United States, 33607

Actively Recruiting

9

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, United States, 21218

Actively Recruiting

10

Washington University St. Louis

St Louis, Missouri, United States, 63130

Actively Recruiting

11

Montefiore Medical Center

The Bronx, New York, United States, 10467

Actively Recruiting

12

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States, 27514

Actively Recruiting

13

Levine Cancer Institute

Charlotte, North Carolina, United States, 28204

Actively Recruiting

14

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

15

UT Southwestern

Dallas, Texas, United States, 75390

Not Yet Recruiting

Loading map...

Research Team

J

Jessica Crimella

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here